BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Accera, Inc. Announces Initiation of Clinical Trial for AC-1204


11/26/2012 10:17:28 AM

BROOMFIELD, Colo., Nov. 26, 2012 /PRNewswire/ -- Accera, Inc., a privately-held, commercial-stage, healthcare company focused on the discovery and development of innovative clinical applications to address acute and chronic neurodegenerative diseases, announced today the initiation of a clinical efficacy trial examining the effects of AC-1204 in patients with mild-to-moderate Alzheimer's disease (AD). AC-1204 is a formulation of caprylic triglyceride designed to improve cognitive function in mild to moderate Alzheimer's disease.

The study, (Titled: NOURISH AD), "A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Subjects with Mild to Moderate Alzheimer's Disease (AD) with an Optional 26 Week Open-Label Extension," will examine the efficacy of 26 weeks daily administration of AC-1204 compared with placebo among participants diagnosed with mild-to-moderate AD.

"With the recent investment we received from Nestlé Health Science, we're eager to generate additional clinical data illustrating the effectiveness of our product in patients with mild-to-moderate Alzheimer's disease," said Holger Kunze, president and CEO of Accera. "We believe we have a truly innovative approach that will meet the needs of patients in this overwhelmingly underserved market."

Accera's technology addresses the well-recognized physiological hallmark of the brain's inability to optimally metabolize glucose by providing an alternative energy source for brain cells. In previous clinical trials, this approach has been shown to safely improve memory and cognitive function by inducing safe, therapeutic, tolerable and predictable levels of ketosis that improves memory in patients with mild-to-moderate AD.

The study will be a randomized, double-blind, placebo-controlled, parallel-group, multi-center trial. It will be conducted at approximately 60 clinical sites in the US and is expected to enroll more than 400 patients. This study will evaluate the effects of once daily dosing of AC-1204 for 26 weeks on cognition, pharmacokinetic measures, activities of daily living, resource utilization, and quality of life among subjects with mild-to-moderate AD.

The primary endpoint will examine the effects of AC-1204 on memory and cognition as measured by the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-Cog) after 26 weeks among both carriers and non carriers of the epsilon 4 variant of the gene apolipoprotein E (APOE4). Previous studies demonstrated proof of concept for the company's unique approach.

About Accera
Accera, Inc. is a privately held commercial-stage healthcare company that developed and now markets Axona in the US. Accera is engaged in the research, development and commercialization of other clinical applications for Axona and AC-1204 in acute and chronic neurodegenerative diseases. For more information about Accera, please visit www.accerapharma.com

Accera, Inc.

Tiberend Strategic Advisors, Inc.

(303) 999-3705

(212) 827-0020

Bill Poncy

Andrew Mielach

VP Commercial Development

amielach@tiberend.com

bponcy@accerapharma.com


SOURCE Accera, Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES